MedElute is a start-up based in Michigan that has been granted a paid up license from Angiotech Pharmaceutical, Inc. as part of the merger transaction between Angiotech and Afmedica, Inc. The license is for rights to a pending patent (not yet issued) in which claims are made for methods and materials to treat post surgical adhesions with a highly anti-platelet approach.
MedElute Frequently Asked Questions (FAQ)
Where is MedElute's headquarters?
MedElute's headquarters is located at Kalamazoo.
What is MedElute's latest funding round?
MedElute's latest funding round is Seed.
Who are the investors of MedElute?
Investors of MedElute include TGap Ventures.
Who are MedElute's competitors?
Competitors of MedElute include Zogenix, Neurelis, Annovis Bio, Intarcia Therapeutics, SpiroGen and 13 more.
Compare MedElute to Competitors
Quark Pharmaceuticals is a development-stage pharmaceutical company discovering and developing RNA interference (RNAi)-based therapeutics.
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
The DNA Repair Company was founded to bring recent scientific discoveries from the Dana Farber Cancer Institute and the Massachusetts Institute of Technology to the clinic to benefit cancer patients. Breakthroughs in understanding DNA repair mechanisms have led to new personalized approaches to cancer treatment, beginning with diagnostic tools that improve the efficacy of currently available cancer therapies, as well as drugs under development. DNAR exists to make these tools available to physicians with the goal of improving clinical outcomes.
ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.
Banyan Biomarkers has created a Point of Care (POC) Blood Test to diagnose traumatic brain injury (TBI). Banyan Biomarkers' research has identified unique biomarkers present in the patient's blood following injury to the brain. The detection and quantification of these biomarkers may provide early indications of brain trauma essential for earlier intervention and management.
Intarcia Therapeutics operates as a biopharmaceutical company. The company develops and commercializes therapies to transform the prevention and management of chronic diseases. The company was founded in 1995 and is based in Boston, Massachusetts.